GotchF.A., KeenM.L.Precise control minimal heparinisation for high bleeding risk haemodialysis.Trans Am Soc Artif Intern Org1977; 23: 168–75.
5.
ZusmannR.M., RubinR.H., CatoA.E., CocchettoD.M., CrowJ.W., Tolkoff-RubinN.Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.N Eng J Med1981; 304: 934–9.
6.
TurneyJ.M., WestonM.J.Dialysis without anticoagulants.Lancet1981; 2: 693.
7.
DamusP.S., HicksM., RosenbergR.D.Anticoagulant action of heparin.Nature (London)1973; 246: 355–7.
8.
AnderssonL.O., BarrowcliffeT.W., HolmerE., JohnsonE.A., SimsG.E.C.Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration.Thromb Res1976; 9: 575–83.
9.
SimsG.E.C.Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration.Thromb Res1976; 9: 575–83.
10.
MoelkerH.C.T.Heparin and platelet function.Progress in Pharmacology.Stuttgart-New York: G. Fisher Verlag1982; 4/4.
11.
SalzmanE.W., RosenbergR.D., SmitM.H., LindlowJ.N., FabreauL.Effect of heparin and heparin fractions on platelet aggregation.J Clin Invest1980; 65: 64–73.
12.
CadeJ.F., BuchananM.R., BoneuB.A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.Thromb Res1984; 35: 613–25.
13.
MeulemanD.C.G., HobbelenP.M.J., van DedemG., MoelkerH.C.T.A novel antithrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.Thromb Res1982; 27: 353–63.
14.
Ten CateH., LampingR.J., HennyChP, PrinsA., Ten CateJ.W.Automated amidolytic method for determining heparin, a heparinoid, and a Low-M heparin fragment, based on their anti-Xa activity.Clin Chem1984; 30: 860–4.
15.
BarrowcliffeT.W., CurtisA.D., TomkinsonT.P.Standardization of low molecular weight heparins: a collaborative study.Throm Haemost1985; 54: 675–9.
16.
HennyChP, Ten CateJ.W., van BronswijkH.Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.Lancet1983; I: 890–3.
17.
HennyChP, Ten CateH., SurachnoS.The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis.Thromb Haemost1985; 54: 460–2.
18.
Ten CateH., HennyChP, ten CateJ.W.Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.Thromb Res1985; 38: 211–22.
19.
LjungbergB.A low molecular heparin fraction as an anticoagulant during haemodialysis.Clin Nephrol1985; 24: 15–20.
20.
SchraderJ., ValentinR., TönnisH.J.Low molecular weight heparin in hemodialysis and hemofiltration patients.Kidney Int1985; 28: 823–9.
21.
RenaudH., MoriniereP., DievalJ.Low molecular weight heparin in haemodialysis and haemofiltration-comparison with unfractionated heparin.Proc EDTA-ERA1984; 21: 276–80.
22.
IrelandH., LaneD.A., FlynnA., AnastassiadesE., CurtisJ.R.The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.Thromb Haem1985; 54: 91.
